Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 4Gastrointestinal Stromal Tumors 4Rectal Neoplasms 3Neoplasm Metastasis 3Melanoma 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Anus Neoplasms 2Xeroderma Pigmentosum 1Waldenstrom Macroglobulinemia 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Thrombocytosis 1Somatostatinoma 1Sezary Syndrome 1Seminoma 1Sarcoma, Kaposi 1Sarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Prostatic Neoplasms 1Primary Myelofibrosis 1

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × CTLA-4 Antigen × Gastrointestinal × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡